0
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Risk assessment for colorectal cancer via polygenic risk score and lifestyle exposure: a large-scale association study of East Asian and European populations

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background

          The genetic architectures of colorectal cancer are distinct across different populations. To date, the majority of polygenic risk scores (PRSs) are derived from European (EUR) populations, which limits their accurate extrapolation to other populations. Here, we aimed to generate a PRS by incorporating East Asian (EAS) and EUR ancestry groups and validate its utility for colorectal cancer risk assessment among different populations.

          Methods

          A large-scale colorectal cancer genome-wide association study (GWAS), harboring 35,145 cases and 288,934 controls from EAS and EUR populations, was used for the EAS-EUR GWAS meta-analysis and the construction of candidate EAS-EUR PRSs via different approaches. The performance of each PRS was then validated in external GWAS datasets of EAS (727 cases and 1452 controls) and EUR (1289 cases and 1284 controls) ancestries, respectively. The optimal PRS was further tested using the UK Biobank longitudinal cohort of 355,543 individuals and ultimately applied to stratify individual risk attached by healthy lifestyle.

          Results

          In the meta-analysis across EAS and EUR populations, we identified 48 independent variants beyond genome-wide significance ( P < 5 × 10 −8) at previously reported loci. Among 26 candidate EAS-EUR PRSs, the PRS-CSx approach-derived PRS (defined as PRS CSx) that harbored genome-wide variants achieved the optimal discriminatory ability in both validation datasets, as well as better performance in the EAS population compared to the PRS derived from known variants. Using the UK Biobank cohort, we further validated a significant dose-response effect of PRS CSx on incident colorectal cancer, in which the risk was 2.11- and 3.88-fold higher in individuals with intermediate and high PRS CSx than in the low score subgroup ( P trend = 8.15 × 10 −53). Notably, the detrimental effect of being at a high genetic risk could be largely attenuated by adherence to a favorable lifestyle, with a 0.53% reduction in 5-year absolute risk.

          Conclusions

          In summary, we systemically constructed an EAS-EUR PRS to effectively stratify colorectal cancer risk, which highlighted its clinical implication among diverse ancestries. Importantly, these findings also supported that a healthy lifestyle could reduce the genetic impact on incident colorectal cancer.

          Supplementary Information

          The online version contains supplementary material available at 10.1186/s13073-023-01156-9.

          Related collections

          Most cited references40

          • Record: found
          • Abstract: found
          • Article: not found

          Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

          This article provides an update on the global cancer burden using the GLOBOCAN 2020 estimates of cancer incidence and mortality produced by the International Agency for Research on Cancer. Worldwide, an estimated 19.3 million new cancer cases (18.1 million excluding nonmelanoma skin cancer) and almost 10.0 million cancer deaths (9.9 million excluding nonmelanoma skin cancer) occurred in 2020. Female breast cancer has surpassed lung cancer as the most commonly diagnosed cancer, with an estimated 2.3 million new cases (11.7%), followed by lung (11.4%), colorectal (10.0 %), prostate (7.3%), and stomach (5.6%) cancers. Lung cancer remained the leading cause of cancer death, with an estimated 1.8 million deaths (18%), followed by colorectal (9.4%), liver (8.3%), stomach (7.7%), and female breast (6.9%) cancers. Overall incidence was from 2-fold to 3-fold higher in transitioned versus transitioning countries for both sexes, whereas mortality varied <2-fold for men and little for women. Death rates for female breast and cervical cancers, however, were considerably higher in transitioning versus transitioned countries (15.0 vs 12.8 per 100,000 and 12.4 vs 5.2 per 100,000, respectively). The global cancer burden is expected to be 28.4 million cases in 2040, a 47% rise from 2020, with a larger increase in transitioning (64% to 95%) versus transitioned (32% to 56%) countries due to demographic changes, although this may be further exacerbated by increasing risk factors associated with globalization and a growing economy. Efforts to build a sustainable infrastructure for the dissemination of cancer prevention measures and provision of cancer care in transitioning countries is critical for global cancer control.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: found
            Is Open Access

            UK Biobank: An Open Access Resource for Identifying the Causes of a Wide Range of Complex Diseases of Middle and Old Age

            Cathie Sudlow and colleagues describe the UK Biobank, a large population-based prospective study, established to allow investigation of the genetic and non-genetic determinants of the diseases of middle and old age.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              GCTA: a tool for genome-wide complex trait analysis.

              For most human complex diseases and traits, SNPs identified by genome-wide association studies (GWAS) explain only a small fraction of the heritability. Here we report a user-friendly software tool called genome-wide complex trait analysis (GCTA), which was developed based on a method we recently developed to address the "missing heritability" problem. GCTA estimates the variance explained by all the SNPs on a chromosome or on the whole genome for a complex trait rather than testing the association of any particular SNP to the trait. We introduce GCTA's five main functions: data management, estimation of the genetic relationships from SNPs, mixed linear model analysis of variance explained by the SNPs, estimation of the linkage disequilibrium structure, and GWAS simulation. We focus on the function of estimating the variance explained by all the SNPs on the X chromosome and testing the hypotheses of dosage compensation. The GCTA software is a versatile tool to estimate and partition complex trait variation with large GWAS data sets.
                Bookmark

                Author and article information

                Contributors
                mwang@njmu.edu.cn
                Journal
                Genome Med
                Genome Med
                Genome Medicine
                BioMed Central (London )
                1756-994X
                24 January 2023
                24 January 2023
                2023
                : 15
                : 4
                Affiliations
                [1 ]GRID grid.89957.3a, ISNI 0000 0000 9255 8984, Department of Environmental Genomics, Jiangsu Key Laboratory of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Cancer Personalized Medicine, , Nanjing Medical University, School of Public Health, Nanjing Medical University, 101 Longmian Avenue, Jiangning District, ; Nanjing, 211166 China
                [2 ]GRID grid.89957.3a, ISNI 0000 0000 9255 8984, Department of Genetic Toxicology, The Key Laboratory of Modern Toxicology of Ministry of Education, Center for Global Health, , School of Public Health, Nanjing Medical University, ; Nanjing, China
                [3 ]GRID grid.89957.3a, ISNI 0000 0000 9255 8984, Department of Biostatistics, Center for Global Health, , School of Public Health, Nanjing Medical University, ; Nanjing, China
                [4 ]GRID grid.89957.3a, ISNI 0000 0000 9255 8984, Department of Oncology, Nanjing First Hospital, , Nanjing Medical University, ; Nanjing, China
                [5 ]GRID grid.411634.5, ISNI 0000 0004 0632 4559, Department of Gastroenterological Surgery, Laboratory of Surgical Oncology, , Beijing Key Laboratory of Colorectal Cancer Diagnosis and Treatment Research, Peking University People’s Hospital, ; No. 11 Xizhimen South Street, Xicheng District, Beijing, China
                [6 ]GRID grid.452404.3, ISNI 0000 0004 1808 0942, Cancer Institute, Fudan University Shanghai Cancer Center, ; Shanghai, China
                [7 ]GRID grid.11841.3d, ISNI 0000 0004 0619 8943, Department of Oncology, , Shanghai Medical College, Fudan University, ; Shanghai, China
                [8 ]GRID grid.13402.34, ISNI 0000 0004 1759 700X, Department of Epidemiology and Biostatistics at School of Public Health, , Zhejiang University School of Medicine, ; Hangzhou, China
                [9 ]GRID grid.13402.34, ISNI 0000 0004 1759 700X, Cancer Institute, The Second Affiliated Hospital, , Zhejiang University School of Medicine, ; Hangzhou, China
                [10 ]GRID grid.13402.34, ISNI 0000 0004 1759 700X, Department of Colorectal Surgery and Oncology, Key Laboratory of Cancer Prevention and Intervention, , Ministry of Education, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, ; Zhejiang, China
                [11 ]GRID grid.13402.34, ISNI 0000 0004 1759 700X, Cancer Center, , Zhejiang University, Hangzhou, ; Zhejiang, China
                [12 ]GRID grid.412676.0, ISNI 0000 0004 1799 0784, Department of Oncology, , The First Affiliated Hospital of Nanjing Medical University, ; Nanjing, China
                [13 ]GRID grid.89957.3a, ISNI 0000 0000 9255 8984, Department of Epidemiology, Center for Global Health, , School of Public Health, Nanjing Medical University, ; Nanjing, China
                [14 ]GRID grid.440227.7, ISNI 0000 0004 1758 3572, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital, Gusu School, Nanjing Medical University, ; Suzhou, China
                Author information
                http://orcid.org/0000-0002-4996-958X
                Article
                1156
                10.1186/s13073-023-01156-9
                9875451
                36694225
                d12244a5-5a8d-4179-8fe3-f124a47968b3
                © The Author(s) 2023

                Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver ( http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

                History
                : 2 October 2022
                : 13 January 2023
                Funding
                Funded by: FundRef http://dx.doi.org/10.13039/501100001809, National Natural Science Foundation of China;
                Award ID: 81822039, 82173601 and 82073631
                Award Recipient :
                Categories
                Research
                Custom metadata
                © The Author(s) 2023

                Molecular medicine
                colorectal cancer,east asian,european,polygenic risk score,lifestyle
                Molecular medicine
                colorectal cancer, east asian, european, polygenic risk score, lifestyle

                Comments

                Comment on this article